Inosine monophosphate dehydrogenase
From Proteopedia
(Difference between revisions)
(6 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | <StructureSection load='Figure_2.pdb' size='350' side='right' scene='Journal:JBSD:1/Cv/1' caption=''> | + | <StructureSection load='Figure_2.pdb' size='350' side='right' scene='Journal:JBSD:1/Cv/1' caption='Human IMPDH ([[1b3o]])'> |
== Function == | == Function == | ||
Line 35: | Line 35: | ||
Stereospecific interaction or recognition of IN to C2 domain through <scene name='Journal:JBSD:1/Cv/12'>conserved water mediated salt bridge (K109 (NZ) --- D215 / D216 and K109 (NZ) --- WII1 --- D215 / D216)</scene> are observed to be unique in hIMPDH–II, which is not observed in type I isoform (1JCN). The geometrical and electronic consequences of <scene name='Journal:JBSD:1/Cv/14'>conserved water molecular interaction as shown in Figure 5 (K109 to acidic D215 / D216 and E217)</scene> and their stereo chemical features (specially in CBS --- IN inter-domain recognition site) may be used to design the actual topology of inhibitor for hIMPDH-II isoform using water mimic inhibitor design protocol. Possibly, heterocyclic ligand with flexible structure containing two or three basic and hydrophilic groups with suitable spacer length may be implemented to design the isoform selective inhibitor for CML cancer. | Stereospecific interaction or recognition of IN to C2 domain through <scene name='Journal:JBSD:1/Cv/12'>conserved water mediated salt bridge (K109 (NZ) --- D215 / D216 and K109 (NZ) --- WII1 --- D215 / D216)</scene> are observed to be unique in hIMPDH–II, which is not observed in type I isoform (1JCN). The geometrical and electronic consequences of <scene name='Journal:JBSD:1/Cv/14'>conserved water molecular interaction as shown in Figure 5 (K109 to acidic D215 / D216 and E217)</scene> and their stereo chemical features (specially in CBS --- IN inter-domain recognition site) may be used to design the actual topology of inhibitor for hIMPDH-II isoform using water mimic inhibitor design protocol. Possibly, heterocyclic ligand with flexible structure containing two or three basic and hydrophilic groups with suitable spacer length may be implemented to design the isoform selective inhibitor for CML cancer. | ||
- | </StructureSection> | ||
==3D structures of inosine monophosphate dehydrogenase== | ==3D structures of inosine monophosphate dehydrogenase== | ||
+ | [[Inosine monophosphate dehydrogenase 3D structures]] | ||
- | + | </StructureSection> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Current revision
|
References
- ↑ Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, Murcko MA, Wilson KP. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell. 1996 Jun 14;85(6):921-30. PMID:8681386
- ↑ Price GM, Hoffbrand AV, Taheri MR, Evans JP. Inosine monophosphate dehydrogenase activity in acute leukaemia. Leuk Res. 1987;11(6):525-8. PMID:2885446
- ↑ Bairagya HR, Mukhopadhyay BP. An insight to the dynamics of conserved water-mediated salt bridge interaction and interdomain recognition in hIMPDH isoforms. J Biomol Struct Dyn. 2012 Aug 28. PMID:22928911 doi:10.1080/07391102.2012.712458